An Indian government’s expert panel has reportedly recommended approval of the vaccine, developed by AstraZeneca (LSE: AZN) and Oxford University for emergency use in India to provide immunity against COVID-19, according to local media reports.
According to news agency Reuters, a subject expert committee set up by Drugs Controller General of India (DCGI) to vet Covid-19 vaccine proposals, has recommended granting emergency use authorization to AstraZeneca’s vaccine AZD1222, dubbed Covishield in India, where it will be produced by the Serum Institute of India.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze